Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
BROMPHENIRAMINE MALEATE vs TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
1 capsule (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4-6 hours; not to exceed 4 doses in 24 hours.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Triprolidine: 5-7 hours. Pseudoephedrine: 4-8 hours (pH-dependent; alkaline urine prolongs half-life). Clinical context: Dose adjustment needed in renal impairment for pseudoephedrine.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Triprolidine: Renal excretion of metabolites (approx. 60%) and unchanged drug (less than 5%). Pseudoephedrine: Primarily renal elimination as unchanged drug (70-90%), with minor hepatic metabolism. Fecal excretion is negligible for both.
Category C
Category A/B
Antihistamine
Antihistamine